NO20043829L - Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel - Google Patents
Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddelInfo
- Publication number
- NO20043829L NO20043829L NO20043829A NO20043829A NO20043829L NO 20043829 L NO20043829 L NO 20043829L NO 20043829 A NO20043829 A NO 20043829A NO 20043829 A NO20043829 A NO 20043829A NO 20043829 L NO20043829 L NO 20043829L
- Authority
- NO
- Norway
- Prior art keywords
- hemicalsium
- atorvastatin
- organic solvent
- essentially free
- desolvating
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 2
- 229960005370 atorvastatin Drugs 0.000 title 2
- 239000003960 organic solvent Substances 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35849702P | 2002-02-19 | 2002-02-19 | |
| PCT/US2003/005216 WO2003070665A2 (en) | 2002-02-19 | 2003-02-19 | Desolvating solvates of atorvastatin hemi-calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043829L true NO20043829L (no) | 2004-09-13 |
Family
ID=27757749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043829A NO20043829L (no) | 2002-02-19 | 2004-09-13 | Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7122681B2 (enExample) |
| EP (1) | EP1465901A4 (enExample) |
| JP (4) | JP4422488B2 (enExample) |
| KR (3) | KR20040086397A (enExample) |
| CN (1) | CN100379723C (enExample) |
| AU (1) | AU2003213171A1 (enExample) |
| CA (1) | CA2475123A1 (enExample) |
| HR (1) | HRP20040767A2 (enExample) |
| IL (1) | IL163594A0 (enExample) |
| IS (1) | IS7407A (enExample) |
| MX (1) | MXPA04007995A (enExample) |
| NO (1) | NO20043829L (enExample) |
| PL (1) | PL372241A1 (enExample) |
| WO (1) | WO2003070665A2 (enExample) |
| ZA (1) | ZA200406229B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| EP1771455B1 (en) * | 2004-07-16 | 2016-05-11 | LEK Pharmaceuticals d.d. | Oxidative degradation products of atorvastatin calcium |
| DE202005020766U1 (de) * | 2004-07-22 | 2006-10-05 | Teva Pharmaceutical Industries Ltd. | Neue Kristallformen von Atorvastatin-Hemi-Calcium |
| MX2007002248A (es) * | 2004-08-25 | 2008-10-02 | Pfizer | Triazolobenzodiazepinas y su uso como antagonistas de vasopresina. |
| JP2008514722A (ja) * | 2004-09-30 | 2008-05-08 | ドクター レディズ ラボラトリーズ リミテッド | 非結晶性アトルバスタチンカルシウム |
| US20090215855A1 (en) * | 2005-04-08 | 2009-08-27 | Jozsef Barkoczy | New Crystalline Atorvastatin Hemicalcium Salt Polymorph Form |
| EP1966133A2 (en) * | 2005-12-13 | 2008-09-10 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IT1390848B1 (it) * | 2008-07-31 | 2011-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| JP6563017B2 (ja) | 2014-08-28 | 2019-08-21 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| US11261183B2 (en) * | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| EP3419976B1 (en) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Acid addition salts of piperazine derivatives |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| LT3630744T (lt) | 2017-05-23 | 2023-03-10 | H. Lundbeck A/S | Pirazolo magl inhibitoriai |
| KR102839500B1 (ko) | 2018-08-22 | 2025-07-28 | 아셰뉴론 에스아 | 글리코시다제 억제제로서 유용한 피페라진 유도체의 숙시네이트 및 푸마레이트 산 부가염 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US444129A (en) * | 1891-01-06 | Henry l | ||
| US4444129A (en) * | 1982-11-05 | 1984-04-24 | Lecorp | Method of drying fine coal particles |
| DE3306250A1 (de) * | 1983-02-23 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | Sphaerische einkristalle fuer pharmazeutische zwecke |
| JPS59167676A (ja) * | 1983-03-11 | 1984-09-21 | 株式会社 大川原製作所 | 多室型流動層乾燥機 |
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| GB8914804D0 (en) * | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| JP3296564B2 (ja) * | 1995-07-17 | 2002-07-02 | ワーナー−ランバート・コンパニー | 結晶性の〔Ｒ−（Ｒ▲上＊▼，Ｒ▲上＊▼）〕−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−〔（フェニルアミノ）カルボニル〕−１Ｈ−ピロール−１−ヘプタン酸ヘミカルシウム塩（アトルバスタチン） |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| TW385306B (en) * | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| KR20020063190A (ko) | 1999-11-17 | 2002-08-01 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 칼슘의 다형태 |
| WO2001044181A1 (en) | 1999-12-17 | 2001-06-21 | Warner Lambert Research And Development Ireland Limited | A process for producing crystalline atorvastatin calcium |
| ATE309985T1 (de) | 1999-12-17 | 2005-12-15 | Pfizer Science & Tech Ltd | Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form |
| CN1535139A (zh) * | 2000-11-03 | 2004-10-06 | ������ҩ��ҵ����˾ | 阿伐他丁半钙形式ⅶ |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| EP1345896B1 (en) | 2000-12-27 | 2009-01-07 | Teva Pharmaceutical Industries Limited | Crystalline forms of atorvastatin |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| IN190564B (enExample) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| CA2450111C (en) * | 2001-06-29 | 2006-02-07 | Warner-Lambert Company Llc | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| CZ2004126A3 (cs) | 2001-07-30 | 2004-12-15 | Dr. Reddy's Laboratories Limited | Krystalické formy VI. A VII. vápenaté soli atorvastatinu |
| CA2456095C (en) | 2001-08-31 | 2010-05-11 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
| CA2475864A1 (en) | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
-
2003
- 2003-02-19 MX MXPA04007995A patent/MXPA04007995A/es active IP Right Grant
- 2003-02-19 IL IL16359403A patent/IL163594A0/xx unknown
- 2003-02-19 EP EP03709217A patent/EP1465901A4/en not_active Withdrawn
- 2003-02-19 CA CA002475123A patent/CA2475123A1/en not_active Abandoned
- 2003-02-19 KR KR10-2004-7012804A patent/KR20040086397A/ko not_active Ceased
- 2003-02-19 WO PCT/US2003/005216 patent/WO2003070665A2/en not_active Ceased
- 2003-02-19 KR KR1020097007464A patent/KR20090045419A/ko not_active Ceased
- 2003-02-19 JP JP2003569575A patent/JP4422488B2/ja not_active Expired - Fee Related
- 2003-02-19 PL PL03372241A patent/PL372241A1/xx unknown
- 2003-02-19 CN CNB038040913A patent/CN100379723C/zh not_active Expired - Fee Related
- 2003-02-19 US US10/370,424 patent/US7122681B2/en not_active Expired - Fee Related
- 2003-02-19 KR KR1020097007465A patent/KR20090045420A/ko not_active Ceased
- 2003-02-19 HR HRP20040767 patent/HRP20040767A2/hr not_active Application Discontinuation
- 2003-02-19 AU AU2003213171A patent/AU2003213171A1/en not_active Abandoned
-
2004
- 2004-08-04 ZA ZA200406229A patent/ZA200406229B/en unknown
- 2004-08-17 IS IS7407A patent/IS7407A/is unknown
- 2004-09-13 NO NO20043829A patent/NO20043829L/no not_active Application Discontinuation
-
2006
- 2006-10-02 US US11/542,339 patent/US20070027328A1/en not_active Abandoned
-
2009
- 2009-02-26 JP JP2009044173A patent/JP2009143957A/ja active Pending
- 2009-07-17 JP JP2009169170A patent/JP2009235100A/ja active Pending
-
2013
- 2013-03-13 JP JP2013050939A patent/JP2013136630A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200406229B (en) | 2006-06-28 |
| IS7407A (is) | 2004-08-17 |
| HRP20040767A2 (en) | 2004-12-31 |
| MXPA04007995A (es) | 2004-11-26 |
| JP2013136630A (ja) | 2013-07-11 |
| AU2003213171A1 (en) | 2003-09-09 |
| CN100379723C (zh) | 2008-04-09 |
| WO2003070665A2 (en) | 2003-08-28 |
| EP1465901A2 (en) | 2004-10-13 |
| PL372241A1 (en) | 2005-07-11 |
| US7122681B2 (en) | 2006-10-17 |
| JP2009143957A (ja) | 2009-07-02 |
| US20030216584A1 (en) | 2003-11-20 |
| IL163594A0 (en) | 2005-12-18 |
| US20070027328A1 (en) | 2007-02-01 |
| KR20090045420A (ko) | 2009-05-07 |
| WO2003070665A3 (en) | 2004-02-12 |
| JP2005523285A (ja) | 2005-08-04 |
| EP1465901A4 (en) | 2006-02-01 |
| JP4422488B2 (ja) | 2010-02-24 |
| KR20090045419A (ko) | 2009-05-07 |
| CN1633439A (zh) | 2005-06-29 |
| KR20040086397A (ko) | 2004-10-08 |
| CA2475123A1 (en) | 2003-08-28 |
| JP2009235100A (ja) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20043829L (no) | Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel | |
| NO20033560D0 (no) | Fremgangsmåte for spektral balansering av forskjövne seismiske data | |
| ATE398105T1 (de) | Carbonylamino- derivativate als neue inhibitoren von histone deacetylase | |
| DE60321808D1 (de) | Flavon derivate als inhibitoren von cyclin-abhängigen kinasen | |
| DK1644384T3 (da) | Fremgangsmåde og mellemprodukter til syntese af entecavir | |
| NO20033491D0 (no) | Heterocykliske inhibitorer av ERK2 og anvendelser derav | |
| NO20043158L (no) | Substituerte kinazolinderivater som inhibitorer av aurorakinaser | |
| DE60221875D1 (de) | 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren | |
| DK1581515T3 (da) | Triazolderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1 | |
| NO20024921D0 (no) | Kombinasjon av organiske forbindelser | |
| NO20024920D0 (no) | Kombinasjon av organiske forbindelser | |
| DE60234167D1 (de) | Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren | |
| NO20043907L (no) | Partielle og fullstendige agonister av A1-adenosinreseptorer | |
| DE60332036D1 (de) | Einteilige hand-airbrush | |
| SE0303102L (sv) | Realtidsanalys av gasblandningar | |
| DK1528923T3 (da) | N-((3-oxo-2,3-dihydro-1H-isoindol-1-yl)-acetyl)guanidinderivater som NHE1-inhibitorer til behandling af infarkt og angina pectoris | |
| DE50202440D1 (de) | Kristalline hydrate von anilid-derivaten als funigizide und insektizide | |
| EA200300925A1 (ru) | Новый способ промышленного синтеза ранелата стронция и его гидратов | |
| NO20042679L (no) | Inhibitorer av cytosolisk fosfolipase A2 | |
| EP1539248A4 (en) | INHIBITOR OF S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF SUPPRESSING CANCER USING THIS HEMMER | |
| NO20044016L (no) | Fremgangsmate for nedad-ekstrapolering av seismiske data | |
| HRP20060124A2 (en) | Process for the preparation of n-amino substituted heterocyclic compounds | |
| DE60323461D1 (de) | Reinigungsvorrichtung zum reinigen von metallischen saiten von musikinstrumenten | |
| DE60308187D1 (de) | N-benzyl-3-phenyl-3-heterocyclyl-propionamid-verbindungen als tachykinin rezeptoren antagonisten und/oder als serotoninwiederaufnahme inhibitoren | |
| NO20033488L (no) | Prövetaking av hydrokarboner fra geologiske formasjoner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |